These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 35057111)

  • 1. Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation.
    Salvati A; Poelstra K
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein corona: challenges and opportunities for targeted delivery of nanomedicines.
    Jiang Z; Chu Y; Zhan C
    Expert Opin Drug Deliv; 2022 Jul; 19(7):833-846. PubMed ID: 35738018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.
    Dawidczyk CM; Kim C; Park JH; Russell LM; Lee KH; Pomper MG; Searson PC
    J Control Release; 2014 Aug; 187():133-44. PubMed ID: 24874289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges.
    Duncan R; Richardson SC
    Mol Pharm; 2012 Sep; 9(9):2380-402. PubMed ID: 22844998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disentangling Biomolecular Corona Interactions With Cell Receptors and Implications for Targeting of Nanomedicines.
    Aliyandi A; Zuhorn IS; Salvati A
    Front Bioeng Biotechnol; 2020; 8():599454. PubMed ID: 33363128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines.
    Caracciolo G
    Nanomedicine; 2015 Apr; 11(3):543-57. PubMed ID: 25555353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted nanomedicine: Lessons learned and future directions.
    Veiga N; Diesendruck Y; Peer D
    J Control Release; 2023 Mar; 355():446-457. PubMed ID: 36773958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual and multi-targeted nanoparticles for site-specific brain drug delivery.
    Luo Y; Yang H; Zhou YF; Hu B
    J Control Release; 2020 Jan; 317():195-215. PubMed ID: 31794799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine.
    Pearce AK; O'Reilly RK
    Bioconjug Chem; 2019 Sep; 30(9):2300-2311. PubMed ID: 31441642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients.
    Bhattacharjee S; Brayden DJ
    Expert Opin Drug Discov; 2021 Mar; 16(3):235-254. PubMed ID: 33108229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions at the cell membrane and pathways of internalization of nano-sized materials for nanomedicine.
    Francia V; Montizaan D; Salvati A
    Beilstein J Nanotechnol; 2020; 11():338-353. PubMed ID: 32117671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlling and Monitoring Intracellular Delivery of Anticancer Polymer Nanomedicines.
    Battistella C; Klok HA
    Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28444959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of nanomedicines for neuron targeting.
    Garcia-Chica J; D Paraiso WK; Tanabe S; Serra D; Herrero L; Casals N; Garcia J; Ariza X; Quader S; Rodriguez-Rodriguez R
    Nanomedicine (Lond); 2020 Jul; 15(16):1617-1636. PubMed ID: 32618490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine.
    Donahue ND; Acar H; Wilhelm S
    Adv Drug Deliv Rev; 2019 Mar; 143():68-96. PubMed ID: 31022434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances of nanomedicines for liver cancer therapy.
    Chi X; Liu K; Luo X; Yin Z; Lin H; Gao J
    J Mater Chem B; 2020 May; 8(17):3747-3771. PubMed ID: 32215381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Killing cancer cells by targeted drug-carrying phage nanomedicines.
    Bar H; Yacoby I; Benhar I
    BMC Biotechnol; 2008 Apr; 8():37. PubMed ID: 18387177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.